Prospective Evaluation of the Pathologic Diagnosis and Treatment Outcomes of Pediatric Burkitt Lymphoma in the Central American Pediatric Hematology-Oncology Association Consortium

PURPOSEClinical and histopathologic diagnosis of pediatric mature B-cell lymphomas (eg, Burkitt lymphoma [BL]) must be accurate to select appropriate risk-based treatment. The Central American Pediatric Hematology-Oncology Association (AHOPCA) in 2000 implemented standardized, resource-adapted treat...

Full description

Saved in:
Bibliographic Details
Main Authors: Priya Kumar, Monika L. Metzger, John K. Choi, Godwin Job, Teresa C. Santiago, Armando Peña, Miguela A. Caniza, Asya Agulnik, Pascale Y. Gassant, Wendy C. Gómez García, Patricia J. Calderón, Claudia Garrido, Roy Rosado, Soad Fuentes Alabí, Valentino Conter, Meenakshi Devidas, Angela K. Carrillo, Yichen Chen, Paola Friedrich, Carlos Rodriguez Galindo, Guillermo L. Chantada, Victor M. Santana
Format: Article
Language:English
Published: American Society of Clinical Oncology 2025-04-01
Series:JCO Global Oncology
Online Access:https://ascopubs.org/doi/10.1200/GO-24-00491
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849701324657000448
author Priya Kumar
Monika L. Metzger
John K. Choi
Godwin Job
Teresa C. Santiago
Armando Peña
Miguela A. Caniza
Asya Agulnik
Pascale Y. Gassant
Wendy C. Gómez García
Patricia J. Calderón
Claudia Garrido
Roy Rosado
Soad Fuentes Alabí
Valentino Conter
Meenakshi Devidas
Angela K. Carrillo
Yichen Chen
Paola Friedrich
Carlos Rodriguez Galindo
Guillermo L. Chantada
Victor M. Santana
author_facet Priya Kumar
Monika L. Metzger
John K. Choi
Godwin Job
Teresa C. Santiago
Armando Peña
Miguela A. Caniza
Asya Agulnik
Pascale Y. Gassant
Wendy C. Gómez García
Patricia J. Calderón
Claudia Garrido
Roy Rosado
Soad Fuentes Alabí
Valentino Conter
Meenakshi Devidas
Angela K. Carrillo
Yichen Chen
Paola Friedrich
Carlos Rodriguez Galindo
Guillermo L. Chantada
Victor M. Santana
author_sort Priya Kumar
collection DOAJ
description PURPOSEClinical and histopathologic diagnosis of pediatric mature B-cell lymphomas (eg, Burkitt lymphoma [BL]) must be accurate to select appropriate risk-based treatment. The Central American Pediatric Hematology-Oncology Association (AHOPCA) in 2000 implemented standardized, resource-adapted treatments for these lymphomas. We evaluated the concordance of local histopathologic diagnoses through central review, determined the impact on therapy selection, and described the clinical characteristics and outcomes of pediatric patients with these lymphomas. We suggest recommendations to improve the accuracy of diagnoses.METHODSPathology samples and reports were submitted by six AHOPCA sites to St Jude Children's Research Hospital for central review. The concordance of sample assessments was evaluated using three criteria: histologic diagnosis, morphology, and immunohistochemistry. Clinical characteristics, treatment, and outcomes were also analyzed.RESULTSOf the 68 eligible patients, 53 (78%) received an accurate pathologic diagnosis of BL. For nine (13%) patients, diagnoses changes with therapy implications were made upon central review, while in six patients, there was a minor disagreement with no therapy implications. Most (87%) patients presented with advanced disease. Detailed cellular features were absent in many reports, and immunohistochemistry was routinely performed at only one site. Of the 50 patients whose treatment data were reported, 44 (88%) completed therapy, five died during treatment, and one abandoned treatment. Treatment outcome was satisfactory: 3-year event-free survival was 74% (SE ± 11%), and overall survival was 73% (SE ± 11%).CONCLUSIONPathology laboratories in limited-resource hospitals and regions need further optimization to increase accurate diagnoses of mature B-cell lymphomas. Creating regional pathology networks will enhance diagnostic support. Despite resource limitations and advanced disease at presentation, the AHOPCA sites' adapted treatment strategies have improved patient outcomes.
format Article
id doaj-art-76e8539968164063a4a051d79f82b0b7
institution DOAJ
issn 2687-8941
language English
publishDate 2025-04-01
publisher American Society of Clinical Oncology
record_format Article
series JCO Global Oncology
spelling doaj-art-76e8539968164063a4a051d79f82b0b72025-08-20T03:17:58ZengAmerican Society of Clinical OncologyJCO Global Oncology2687-89412025-04-011110.1200/GO-24-00491Prospective Evaluation of the Pathologic Diagnosis and Treatment Outcomes of Pediatric Burkitt Lymphoma in the Central American Pediatric Hematology-Oncology Association ConsortiumPriya Kumar0Monika L. Metzger1John K. Choi2Godwin Job3Teresa C. Santiago4Armando Peña5Miguela A. Caniza6Asya Agulnik7Pascale Y. Gassant8Wendy C. Gómez García9Patricia J. Calderón10Claudia Garrido11Roy Rosado12Soad Fuentes Alabí13Valentino Conter14Meenakshi Devidas15Angela K. Carrillo16Yichen Chen17Paola Friedrich18Carlos Rodriguez Galindo19Guillermo L. Chantada20Victor M. Santana21Department of Pathology, St Jude Children's Research Hospital, Memphis, TNDepartment of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TNDepartment of Pathology, St Jude Children's Research Hospital, Memphis, TNDepartment of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TNDepartment of Pathology, St Jude Children's Research Hospital, Memphis, TNPediatric Hematology/Oncology Service, Hospital Escuela Universitario, Tegucigalpa, HondurasDepartment of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TNDepartment of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TNDepartment of Pediatric Oncology, Hospital Saint Damien, Port-au-Prince, HaitiDepartment of Oncology, Hospital Infantil Dr Robert Reid Cabral, Santo Domingo, República DominicanaDepartment of Pediatrics, Hematology/Oncology, Hospital Infantil Manuel de Jesus Rivera La Mascota, Managua, NicaraguaDepartment of Pediatrics, Unidad de Oncologia Pediátrica, Francisco Marroquin University, School of Medicine, Guatemala City, GuatemalaDepartment of Pediatrics, Unidad de Oncologia Pediátrica, Francisco Marroquin University, School of Medicine, Guatemala City, GuatemalaDepartment of Pediatric Oncology, Hospital de Niños Benjamin Bloom, San Salvador, El SalvadorPediatric Hemato-Oncology, Fondazione Tettamanti, IRCCS San Gerardo, Monza, ItalyDepartment of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TNDepartment of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TNDepartment of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TNDepartment of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TNDepartment of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TNDepartment of Hematology/Oncology, Institut de Recerca Sant Joan de Deu; Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Barcelona, SpainDepartment of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TNPURPOSEClinical and histopathologic diagnosis of pediatric mature B-cell lymphomas (eg, Burkitt lymphoma [BL]) must be accurate to select appropriate risk-based treatment. The Central American Pediatric Hematology-Oncology Association (AHOPCA) in 2000 implemented standardized, resource-adapted treatments for these lymphomas. We evaluated the concordance of local histopathologic diagnoses through central review, determined the impact on therapy selection, and described the clinical characteristics and outcomes of pediatric patients with these lymphomas. We suggest recommendations to improve the accuracy of diagnoses.METHODSPathology samples and reports were submitted by six AHOPCA sites to St Jude Children's Research Hospital for central review. The concordance of sample assessments was evaluated using three criteria: histologic diagnosis, morphology, and immunohistochemistry. Clinical characteristics, treatment, and outcomes were also analyzed.RESULTSOf the 68 eligible patients, 53 (78%) received an accurate pathologic diagnosis of BL. For nine (13%) patients, diagnoses changes with therapy implications were made upon central review, while in six patients, there was a minor disagreement with no therapy implications. Most (87%) patients presented with advanced disease. Detailed cellular features were absent in many reports, and immunohistochemistry was routinely performed at only one site. Of the 50 patients whose treatment data were reported, 44 (88%) completed therapy, five died during treatment, and one abandoned treatment. Treatment outcome was satisfactory: 3-year event-free survival was 74% (SE ± 11%), and overall survival was 73% (SE ± 11%).CONCLUSIONPathology laboratories in limited-resource hospitals and regions need further optimization to increase accurate diagnoses of mature B-cell lymphomas. Creating regional pathology networks will enhance diagnostic support. Despite resource limitations and advanced disease at presentation, the AHOPCA sites' adapted treatment strategies have improved patient outcomes.https://ascopubs.org/doi/10.1200/GO-24-00491
spellingShingle Priya Kumar
Monika L. Metzger
John K. Choi
Godwin Job
Teresa C. Santiago
Armando Peña
Miguela A. Caniza
Asya Agulnik
Pascale Y. Gassant
Wendy C. Gómez García
Patricia J. Calderón
Claudia Garrido
Roy Rosado
Soad Fuentes Alabí
Valentino Conter
Meenakshi Devidas
Angela K. Carrillo
Yichen Chen
Paola Friedrich
Carlos Rodriguez Galindo
Guillermo L. Chantada
Victor M. Santana
Prospective Evaluation of the Pathologic Diagnosis and Treatment Outcomes of Pediatric Burkitt Lymphoma in the Central American Pediatric Hematology-Oncology Association Consortium
JCO Global Oncology
title Prospective Evaluation of the Pathologic Diagnosis and Treatment Outcomes of Pediatric Burkitt Lymphoma in the Central American Pediatric Hematology-Oncology Association Consortium
title_full Prospective Evaluation of the Pathologic Diagnosis and Treatment Outcomes of Pediatric Burkitt Lymphoma in the Central American Pediatric Hematology-Oncology Association Consortium
title_fullStr Prospective Evaluation of the Pathologic Diagnosis and Treatment Outcomes of Pediatric Burkitt Lymphoma in the Central American Pediatric Hematology-Oncology Association Consortium
title_full_unstemmed Prospective Evaluation of the Pathologic Diagnosis and Treatment Outcomes of Pediatric Burkitt Lymphoma in the Central American Pediatric Hematology-Oncology Association Consortium
title_short Prospective Evaluation of the Pathologic Diagnosis and Treatment Outcomes of Pediatric Burkitt Lymphoma in the Central American Pediatric Hematology-Oncology Association Consortium
title_sort prospective evaluation of the pathologic diagnosis and treatment outcomes of pediatric burkitt lymphoma in the central american pediatric hematology oncology association consortium
url https://ascopubs.org/doi/10.1200/GO-24-00491
work_keys_str_mv AT priyakumar prospectiveevaluationofthepathologicdiagnosisandtreatmentoutcomesofpediatricburkittlymphomainthecentralamericanpediatrichematologyoncologyassociationconsortium
AT monikalmetzger prospectiveevaluationofthepathologicdiagnosisandtreatmentoutcomesofpediatricburkittlymphomainthecentralamericanpediatrichematologyoncologyassociationconsortium
AT johnkchoi prospectiveevaluationofthepathologicdiagnosisandtreatmentoutcomesofpediatricburkittlymphomainthecentralamericanpediatrichematologyoncologyassociationconsortium
AT godwinjob prospectiveevaluationofthepathologicdiagnosisandtreatmentoutcomesofpediatricburkittlymphomainthecentralamericanpediatrichematologyoncologyassociationconsortium
AT teresacsantiago prospectiveevaluationofthepathologicdiagnosisandtreatmentoutcomesofpediatricburkittlymphomainthecentralamericanpediatrichematologyoncologyassociationconsortium
AT armandopena prospectiveevaluationofthepathologicdiagnosisandtreatmentoutcomesofpediatricburkittlymphomainthecentralamericanpediatrichematologyoncologyassociationconsortium
AT miguelaacaniza prospectiveevaluationofthepathologicdiagnosisandtreatmentoutcomesofpediatricburkittlymphomainthecentralamericanpediatrichematologyoncologyassociationconsortium
AT asyaagulnik prospectiveevaluationofthepathologicdiagnosisandtreatmentoutcomesofpediatricburkittlymphomainthecentralamericanpediatrichematologyoncologyassociationconsortium
AT pascaleygassant prospectiveevaluationofthepathologicdiagnosisandtreatmentoutcomesofpediatricburkittlymphomainthecentralamericanpediatrichematologyoncologyassociationconsortium
AT wendycgomezgarcia prospectiveevaluationofthepathologicdiagnosisandtreatmentoutcomesofpediatricburkittlymphomainthecentralamericanpediatrichematologyoncologyassociationconsortium
AT patriciajcalderon prospectiveevaluationofthepathologicdiagnosisandtreatmentoutcomesofpediatricburkittlymphomainthecentralamericanpediatrichematologyoncologyassociationconsortium
AT claudiagarrido prospectiveevaluationofthepathologicdiagnosisandtreatmentoutcomesofpediatricburkittlymphomainthecentralamericanpediatrichematologyoncologyassociationconsortium
AT royrosado prospectiveevaluationofthepathologicdiagnosisandtreatmentoutcomesofpediatricburkittlymphomainthecentralamericanpediatrichematologyoncologyassociationconsortium
AT soadfuentesalabi prospectiveevaluationofthepathologicdiagnosisandtreatmentoutcomesofpediatricburkittlymphomainthecentralamericanpediatrichematologyoncologyassociationconsortium
AT valentinoconter prospectiveevaluationofthepathologicdiagnosisandtreatmentoutcomesofpediatricburkittlymphomainthecentralamericanpediatrichematologyoncologyassociationconsortium
AT meenakshidevidas prospectiveevaluationofthepathologicdiagnosisandtreatmentoutcomesofpediatricburkittlymphomainthecentralamericanpediatrichematologyoncologyassociationconsortium
AT angelakcarrillo prospectiveevaluationofthepathologicdiagnosisandtreatmentoutcomesofpediatricburkittlymphomainthecentralamericanpediatrichematologyoncologyassociationconsortium
AT yichenchen prospectiveevaluationofthepathologicdiagnosisandtreatmentoutcomesofpediatricburkittlymphomainthecentralamericanpediatrichematologyoncologyassociationconsortium
AT paolafriedrich prospectiveevaluationofthepathologicdiagnosisandtreatmentoutcomesofpediatricburkittlymphomainthecentralamericanpediatrichematologyoncologyassociationconsortium
AT carlosrodriguezgalindo prospectiveevaluationofthepathologicdiagnosisandtreatmentoutcomesofpediatricburkittlymphomainthecentralamericanpediatrichematologyoncologyassociationconsortium
AT guillermolchantada prospectiveevaluationofthepathologicdiagnosisandtreatmentoutcomesofpediatricburkittlymphomainthecentralamericanpediatrichematologyoncologyassociationconsortium
AT victormsantana prospectiveevaluationofthepathologicdiagnosisandtreatmentoutcomesofpediatricburkittlymphomainthecentralamericanpediatrichematologyoncologyassociationconsortium